Pfizer and biontech submit for u.s. emergency use authorization of an additional booster dose of their covid-19 vaccine for older adults

New york and mainz, germany, march 15, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced the companies have submitted an application to the u.s. food and drug administration (fda) for emergency use authorization (eua) of an additional booster dose adults 65 years of age and older who have received an initial booster of any of the authorized or approved covid-19 vaccines. the submission is based on two real-world data sets from israel analyzed at a time when the omicron variant was widely circulating. both data sets showed evidence that an additional mrna booster increases immunogenicity and lowers rates of confirmed infections and severe illness.
BNTX Ratings Summary
BNTX Quant Ranking